Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesSalarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-02-12T21:10:09.358590Z
Market Cap
2.21M

Momentum Score

…

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.43
Low
1.87
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-15.84M
Debt / Equity
0.05
ROE
-193.68%
Net Debt
-5.61M
ROCE
-243.89%
Diluted EPS TTM
-2.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -12.54M -31.61M -12.77M -7.35M -6.94M
Net income -12.54M -31.37M -12.70M -7.10M -5.61M
Selling general administrative 5.72M 7.14M 6.10M 6.11M 7.71M
Selling and marketing expenses 5.71M - - - -
Gross profit -0.01M -0.01M 1.82M 5.23M 3.46M
Reconciled depreciation 0.01M 0.01M 0.02M 0.02M 0.13M
Ebit -12.89M -31.84M -12.81M -7.79M -9.58M
Ebitda -12.88M -14.12M -12.86M -7.85M -9.45M
Depreciation and amortization 0.01M 17.72M -0.04M -0.06M 0.13M
Non operating income net other - - - 0.44M 1.31M
Operating income -12.89M -31.84M -12.81M -7.79M -9.58M
Other operating expenses 12.89M 22.98M 14.65M 12.84M 11.73M
Interest expense - 0.23M 0.04M 0.00M 0.00M
Interest income 0.36M 0.22M - - 1.33M
Net interest income 0.36M 0.22M -0.00M -0.00M 0.02M
Extraordinary items - - - - 0.00M
Income tax expense -0.00M -0.23M -0.06M -0.26M -1.33M
Total revenue 0.00M 0.00M 1.84M 5.23M 3.47M
Total operating expenses 12.88M 22.98M 14.65M 12.84M 11.73M
Cost of revenue 0.01M 0.01M 0.02M 0.01M 0.00M
Total other income expense net 0.35M 0.23M 0.04M 0.43M 2.64M
Discontinued operations - - - - 0.00M
Net income from continuing ops -18.03M -31.61M -12.77M -7.35M -6.94M
Net income applicable to common shares - -31.61M -12.77M -7.75M -6.94M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6.59M 14.65M 40.83M 24.93M 13.89M
Other current assets 0.62M 2.41M 0.95M 0.82M 0.96M
Total liab 1.30M 4.27M 2.11M 2.77M 3.31M
Total stockholder equity 5.29M 10.38M 38.72M 22.16M 10.58M
Other current liab 0.41M 1.41M 0.57M 0.06M 0.48M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -76.35M -63.81M -32.20M -19.43M -12.08M
Good will - 0.00M 8.87M 8.87M 8.87M
Other assets 0.00M 0.13M 1.80M 0.25M 0.31M
Cash 5.90M 12.11M 29.21M 11.12M 3.74M
Total current liabilities 1.30M 4.27M 2.11M 2.77M 3.31M
Current deferred revenue - - - 0.38M 0.54M
Net debt -5.61M -12.11M -29.21M -10.64M -3.24M
Short term debt 0.29M - - 0.48M 0.50M
Short long term debt 0.29M - - 0.48M 0.50M
Short long term debt total 0.29M - - 0.48M 0.50M
Other stockholder equity 81.63M 74.19M 70.92M 41.59M 22.66M
Property plant equipment - - 0.01M 0.02M 0.03M
Total current assets 6.52M 14.52M 30.16M 15.80M 4.69M
Net tangible assets - 10.38M 29.86M 13.29M 1.71M
Net receivables - 1.61M - 3.86M -
Inventory - -1.61M - - -
Accounts payable 0.60M 2.86M 1.54M 1.85M 1.79M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -19.43M -12.08M
Non currrent assets other 0.07M 0.13M 1.80M 0.25M 0.31M
Non current assets total 0.07M 0.13M 10.67M 9.14M 9.20M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00M -1.50M -1.50M -0.00M 5.61M
Change to liabilities - 1.31M -0.31M -0.54M -0.84M
Total cashflows from investing activities - -1.50M -1.50M -0.00M 5.61M
Net borrowings - - -0.48M -0.97M -0.42M
Total cash from financing activities 6.64M 1.99M 28.30M 17.69M 3.58M
Change to operating activities - 1.06M 0.10M 1.36M -0.23M
Net income -12.54M -31.61M -12.77M -7.35M -6.94M
Change in cash -6.21M -17.11M 18.10M 7.38M -2.39M
Begin period cash flow 12.11M 29.21M 11.12M 3.74M 6.13M
End period cash flow 5.90M 12.11M 29.21M 11.12M 3.74M
Total cash from operating activities -12.85M -17.60M -10.20M -10.31M -11.58M
Issuance of capital stock 6.92M 1.99M 27.29M 14.80M 4.13M
Depreciation 0.01M 0.01M 0.02M 0.02M 0.13M
Other cashflows from investing activities - - - - 5.61M
Dividends paid - - - 0.00M 0.13M
Change to inventory -0.00M - -2.25M 3.86M 0.00M
Change to account receivables 1.48M - 2.25M -3.86M 0.00M
Sale purchase of stock - - - 18.67M -3.71M
Other cashflows from financing activities 0.01M 0.00M 1.49M 3.87M 3.71M
Change to netincome - 11.64M 0.51M 0.06M -0.56M
Capital expenditures 0.00M 1.50M 0.00M 0.00M 0.00M
Change receivables - - - -3.86M 0.00M
Cash flows other operating - - - 0.60M -3.37M
Cash and cash equivalents changes - - - 7.38M -2.39M
Change in working capital -0.97M 2.37M 2.03M -3.04M -4.21M
Stock based compensation 0.52M 0.80M 0.56M 0.32M 0.75M
Other non cash items 1.45M 10.84M -0.04M -0.26M -1.31M
Free cash flow -12.85M -19.10M -10.20M -10.31M -11.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

2450 Holcombe Boulevard, Houston, TX, United States, 77021

832 834 6992

https://www.salariuspharma.com

2

Name Title Year Born
Mr. David J. Arthur M.B.A. CEO, Pres & Director 1963
Mr. Mark J. Rosenblum CPA Exec. VP of Fin. & CFO 1953
Dr. Nadeem Q. Mirza M.D., M.P.H. Sr. VP of Clinical Devel. NA
Dr. Daniela Y. Santiesteban Director of Targeted Protein Degradation Program NA
Mr. David J. Arthur M.B.A. CEO, President & Director 1963
Mr. Mark J. Rosenblum CPA Executive VP of Finance & CFO 1953
Dr. Nadeem Q. Mirza M.D., M.P.H. Senior Vice President of Clinical Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…